Compare Amylx Pharmaceuticals Inc (AMLX) vs Mattel Inc (MAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Mattel Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Mattel Inc trades at $13.36 (market cap $3.87B). The key difference: Mattel Inc is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | MAT | |
|---|---|---|
Market Cap | $1.98B | $3.87B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $22.16 |
52-Week Low | $7.64 | $13.05 |
Enterprise Value | $1.70B | $5.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
MAT trades at $13.33, up 1.14% today, with a bearish technical signal from moving averages and oscillators showing neutral RSI levels. The company reported a net income of $397.58M in 2025, with a P/E of 8.54 and ROE of 23.56% indicating solid profitability. Recent news includes expansion of UNO Social Clubs and upcoming Q2 2026 earnings release on August 4, 2026.
The stock presents a mixed outlook: analyst consensus is a Buy with a $14.50 price target, but recent earnings misses and a negative net cash flow of -$145M in 2025 pose risks. Upside potential exists from brand expansions and Comic-Con product launches, while competitive pressures and debt levels of $2.33B require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
